Hemophilia is a rare disorder that is complex to diagnose and manage. By compiling the second edition of its Guidelines for the Management of Hemophilia, the World Federation of Hemophilia (WFH) aims to provide practical, evidence-based guidance to healthcare providers, government authorities, and patient organizations seeking to initiate and/or maintain hemophilia care programs. It is also hoped these guidelines will encourage practice harmonization around the world and, where recommendations lack adequate evidence, stimulate appropriate studies.
Read a commentary on the guidelines, by Mike Makris and Carol Kasper, in Haemophilia.
Updates to the Guidelines for the Management of Hemophilia
This document tracks changes (2013) that have been made since the 2nd edition was first published in July 2012.
The WFH recently endorsed the NHF-McMaster Guideline on Care Models for Hemophilia Management.Click here to view the full text of the guideline, published in the Journal of Haemophilia, June 27, 2016, or here to read the Executive Summary of the NHF-McMaster guideline.
NOW AVAILABLE: Explore the WFH hemophilia management recommendations in 6 dynamic illustrated eLearning modules, in English, French, and Spanish!
Each module consists of the text of one section of the WFH Guidelines for the Management of Hemophilia, brought to life with detailed colour illustrations, interactive features, a glossary of terms, and linked resources for further reading. There are even quizzes, and progress checks so that you can evaluate whether you have fully understood the content. You can work through an entire module or look up sections of particular interest in the table of contents. These eLearning modules render the complex and important information in the WFH Guidelines for the Management of Hemophilia accessible to everyone.
|1.1||What is hemophilia?||1.7||Home therapy|
|1.2||Principles of care||1.8||Monitoring health status and outcome|
|1.3||Comprehensive care||1.9||Pain management|
|1.4||Fitness and physical activity||1.10||Surgery and invasive procedures|
|1.5||Adjunctive management||1.11||Dental care and management|
|1.6||Prophylactic factor replacement therapy|
|2.2||Genetic testing/counselling and prenatal diagnosis||2.6||Sexuality|
|2.3||Delivery of infants with known or suspected hemophilia||2.7||Ageing hemophilia patients|
|2.4||Vaccinations||2.8||Von Willebrand disease and rare bleeding disorders|
|3.1||Knowledge and expertise in coagulation laboratory testing|
|3.2||Use of the correct equipment and reagents|
|5.1||Joint hemorrhage||5.7||Ophthalmic hemorrhage|
|5.2||Muscle hemorrhage||5.8||Renal hemorrhage|
|5.3||Central nervous system||5.9||Oral hemorrhage|
|5.4||Throat and neck hemorrhage||5.10||Epistaxis|
|5.5||Acute gastrointestinal hemorrhage||5.11||Soft tissue hemorrhage|
|5.6||Acute abdominal hemorrhage||5.12||Lacerations and abrasions|
|6.3||Transfusion-transmitted and other infection-related complications|
Tables and Figures
|Table 1-1:||Relationship of bleeding severity to clotting factor level|
|Table 1-2:||Sites of bleeding in hemophilia|
|Table 1-3:||Approximate frequency of bleeding at different sites|
|Table 1-4:||Definitions of factor replacement therapy protocols|
|Table 1-5:||Strategies for pain management in patients with hemophilia|
|Table 1-6:||Definition of adequacy of hemostasis for surgical procedures|
|Table 3-1:||Interpretation of screening tests|
|Table 5-1:||Definition of response to treatment of acute hemarthrosis|
|Table 7-1:||Suggested plasma factor peak level and duration of administration (when there is no significant resource constraint)|
|Table 7-2:||Plasma factor peak level and duration of administration (when there is significant resource constraint)|
|Figure 7-1:||Strategies for clotting factor replacement at different ages and impact on outcomes|